Ra Pharma

Toleranzia

This company develops drugs using an immune tolerance platform to treat patients with rare autoimmune diseases, such as myasthenia gravis.

NMD Pharma

This company develops small molecule therapies for patients suffering from severe neuromuscular disorders to restore skeletal muscle function.

Chord Therapeutics

This clinical-stage biopharmaceutical company develops drugs for patients with rare neuroinflammatory diseases, including neuromyelitis optica spectrum disorder and generalized myasthenia gravis.

AsclepiX Therapeutics

This biopharmaceutical firm develops peptide therapeutics for patients with retinal diseases and cancer using a computational biology platform.

APLS

This biopharmaceutical company develops complement-based therapies to treat autoimmune and inflammatory diseases for patients with conditions like paroxysmal nocturnal haemoglobinuria and geographic atrophy.

ARTHEx Biotech

This clinical-stage biotechnology company develops RNA-based treatments for patients with rare neuromuscular genetic diseases, including myotonic dystrophy type 1.

GondolaBio

This biopharmaceutical company develops clinical-stage and preclinical medicinal therapeutics for patients living with rare genetic diseases.

immunoforge

This biopharmaceutical company develops therapies for muscular and rare diseases by leveraging a long-acting platform technology to extend the half-life of peptide-based drugs.